The current coronavirus outbreak in China could cause a potential supply chain disruption for US biopharma companies, although some key players such as Bayer and Johnson & Johnson say they have policies in place to minimize disruption. The industry is expecting a mixed impact depending on the type of drugs the pharma company produces, according to credit rating service Moody's.
Coronavirus to have mixed impact on pharma supply chain
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.